Compare UTMD & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTMD | ANIK |
|---|---|---|
| Founded | 1978 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 200.9M |
| IPO Year | 1994 | 1996 |
| Metric | UTMD | ANIK |
|---|---|---|
| Price | $72.08 | $21.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 28.2K | ★ 95.1K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ 1.66 | N/A |
| Revenue | $38,520,000.00 | ★ $112,819,000.00 |
| Revenue This Year | N/A | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | $87.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $53.66 | $8.22 |
| 52 Week High | $75.75 | $22.88 |
| Indicator | UTMD | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 67.23 |
| Support Level | $64.98 | $14.13 |
| Resistance Level | $75.38 | N/A |
| Average True Range (ATR) | 2.15 | 1.38 |
| MACD | 0.13 | 0.35 |
| Stochastic Oscillator | 63.87 | 79.11 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.